These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36527892)

  • 1. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
    Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
    Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
    Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
    Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
    Lafont V; Liautard J; Liautard JP; Favero J
    J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.
    Nedellec S; Sabourin C; Bonneville M; Scotet E
    J Immunol; 2010 Jul; 185(1):55-63. PubMed ID: 20511557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
    Hoeres T; Smetak M; Pretscher D; Wilhelm M
    Front Immunol; 2018; 9():800. PubMed ID: 29725332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
    Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
    Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
    Bonneville M; Scotet E
    Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.
    Laplagne C; Ligat L; Foote J; Lopez F; Fournié JJ; Laurent C; Valitutti S; Poupot M
    Cell Mol Immunol; 2021 Aug; 18(8):1861-1870. PubMed ID: 34183807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
    Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
    Front Immunol; 2022; 13():915837. PubMed ID: 35784326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
    Castella B; Vitale C; Coscia M; Massaia M
    Cell Mol Life Sci; 2011 Jul; 68(14):2419-32. PubMed ID: 21584812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
    Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
    J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
    Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
    Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells.
    Chauvin C; Joalland N; Perroteau J; Jarry U; Lafrance L; Willem C; Retière C; Oliver L; Gratas C; Gautreau-Rolland L; Saulquin X; Vallette FM; Vié H; Scotet E; Pecqueur C
    Clin Cancer Res; 2019 Dec; 25(23):7218-7228. PubMed ID: 31506386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.